Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
作者信息
Rodon Philippe, Hulin Cyrille, Pegourie Brigitte, Tiab Mourad, Anglaret Bruno, Benboubker Lotfi, Jardel Henry, Decaux Olivier, Kolb Brigitte, Roussel Murielle, Garderet Laurent, Leleu Xavier, Fitoussi Olivier, Chaleteix Carine, Casassus Philippe, Lenain Pascal, Royer Bruno, Banos Anne, Benramdane Riad, Cony-Makhoul Pascale, Dib Mamoun, Fontan Jean, Stoppa Anne-Marie, Traullé Catherine, Vilque Jean-Pierre, Pétillon Marie-Odile, Mathiot Claire, Dejoie Thomas, Avet-Loiseau Hervé, Moreau Philippe
机构信息
Hospital Center, Périgueux
University Hospital, Nancy.
出版信息
Haematologica. 2015 Feb;100(2):e56-9. doi: 10.3324/haematol.2014.110890. Epub 2014 Nov 14.
Abstract
摘要
相似文献
1
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
Haematologica. 2015 Feb;100(2):e56-9. doi: 10.3324/haematol.2014.110890. Epub 2014 Nov 14.
2
Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
Leuk Lymphoma. 2014 May;55(5):1191-3. doi: 10.3109/10428194.2013.820289. Epub 2013 Aug 13.
3
Bendamustine: the remedy that came in from the cold.
Blood. 2014 Feb 13;123(7):948-50. doi: 10.1182/blood-2013-12-539817.
4
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
Blood. 2014 Feb 13;123(7):985-91. doi: 10.1182/blood-2013-08-521468. Epub 2013 Nov 13.
5
What is the correct philosophy for the treatment of multiple myeloma?
Leuk Lymphoma. 2007 Dec;48(12):2298-9. doi: 10.1080/10428190701704639.
6
Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma.
Leuk Lymphoma. 2007 Dec;48(12):2345-51. doi: 10.1080/10428190701694194.
7
Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide.
Leuk Lymphoma. 2010 May;51(5):937-40. doi: 10.3109/10428191003695660.
8
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Br J Haematol. 2013 Feb;160(3):321-30. doi: 10.1111/bjh.12129. Epub 2012 Nov 15.
9
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.
Haematologica. 2015 Jan;100(1):100-6. doi: 10.3324/haematol.2014.112037. Epub 2014 Sep 26.
10
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
J Clin Oncol. 2013 Sep 10;31(26):3279-87. doi: 10.1200/JCO.2012.48.4626. Epub 2013 Jul 29.
引用本文的文献
1
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.
Am J Hematol. 2024 Sep;99(9):1802-1824. doi: 10.1002/ajh.27422. Epub 2024 Jun 28.
2
Efficacy of Bendamustine, Pomalidomide, and Dexamethasone (BPD) Regimen in Relapsed/Refractory Extramedullary Myeloma: A Retrospective Single-Centre Study, Real-Life Experience.
Hematol Rep. 2023 Aug 2;15(3):465-473. doi: 10.3390/hematolrep15030048.
3
30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma.
Cancers (Basel). 2023 Mar 23;15(7):1929. doi: 10.3390/cancers15071929.
4
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
Am J Hematol. 2022 Aug;97(8):1086-1107. doi: 10.1002/ajh.26590. Epub 2022 May 23.
5
Genome Instability in Multiple Myeloma: Facts and Factors.
Cancers (Basel). 2021 Nov 26;13(23):5949. doi: 10.3390/cancers13235949.
6
Current and Novel Alkylators in Multiple Myeloma.
Cancers (Basel). 2021 May 18;13(10):2465. doi: 10.3390/cancers13102465.
7
Multiple myeloma current treatment algorithms.
Blood Cancer J. 2020 Sep 28;10(9):94. doi: 10.1038/s41408-020-00359-2.
8
Novel Agents in Multiple Myeloma.
Cancer J. 2019 Jan/Feb;25(1):45-53. doi: 10.1097/PPO.0000000000000355.
9
Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management.
Am J Hematol. 2018 Aug 16;93(8):981-1114. doi: 10.1002/ajh.25117.
10
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
Br J Haematol. 2017 May;177(3):404-413. doi: 10.1111/bjh.14549. Epub 2017 Feb 17.
本文引用的文献
1
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18.
2
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551.
3
Bendamustine: the remedy that came in from the cold.
Blood. 2014 Feb 13;123(7):948-50. doi: 10.1182/blood-2013-12-539817.
4
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.
Blood Cancer J. 2013 Nov 22;3(11):e162. doi: 10.1038/bcj.2013.58.
5
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
Blood. 2014 Feb 13;123(7):985-91. doi: 10.1182/blood-2013-08-521468. Epub 2013 Nov 13.
6
The era of combination therapy in myeloma.
J Clin Oncol. 2012 Jul 10;30(20):2434-6. doi: 10.1200/JCO.2011.40.6967. Epub 2012 May 14.
7
Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program.
Leuk Lymphoma. 2012 Apr;53(4):632-4. doi: 10.3109/10428194.2011.622422. Epub 2011 Nov 25.
8
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.
Blood. 2011 Aug 4;118(5):1239-47. doi: 10.1182/blood-2011-03-341669. Epub 2011 Jun 13.
9
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
N Engl J Med. 2008 Aug 28;359(9):906-17. doi: 10.1056/NEJMoa0801479.
10
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
N Engl J Med. 2007 Nov 22;357(21):2123-32. doi: 10.1056/NEJMoa070594.
Zotero 插件